Journal article
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, D Hogg, A Hill, I Márquez-Rodas, J Haanen, M Guidoboni, M Maio, P Schöffski, MS Carlino Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2019
Abstract
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial. METHODS We randomly assigned patients with previously untreated advanced melanoma to receive one of the following regimens: nivolumab (at a dose of 1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram every 2 weeks); nivolumab (3 mg per kilogram every 2 weeks) plus ipilimumab-matched placebo; or ipilimumab (3 mg per kilogram every 3 weeks for four doses) plus nivolumab-matched..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Supported by Bristol-Myers Squibb, a grant (P30CA008748, to Dr. Wolchok) from the National Cancer Institute, and a grant (to Dr. Larkin) from the National Institute for Health Research Royal Marsden-Institute of Cancer Research Biomedical Research Centre.